Fatigue - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fatigue - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fatigue - Pipeline Review, H2 2014', provides an overview of the Fatigue's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatigue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatigue and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fatigue
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fatigue and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fatigue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatigue pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fatigue
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fatigue Overview 6
Therapeutics Development 7
Pipeline Products for Fatigue - Overview 7
Pipeline Products for Fatigue - Comparative Analysis 8
Fatigue - Therapeutics under Development by Companies 9
Fatigue - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Fatigue - Products under Development by Companies 14
Fatigue - Companies Involved in Therapeutics Development 15
Teva Pharmaceutical Industries Limited 15
Hemispherx Biopharma, Inc. 16
MultiCell Technologies, Inc. 17
Alder Biopharmaceuticals Inc. 18
Biovista Inc. 19
PharmaLundensis AB 20
Merz Pharmaceuticals GmbH 21
Fatigue - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
rintatolimod - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
armodafinil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
clazakizumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
(lofepramine + phenylalanine) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Iodinated Activated Charcoal - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MRZ-9547 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule for Chronic Fatigue Syndrome - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Fatigue - Recent Pipeline Updates 42
Fatigue - Dormant Projects 50
Fatigue - Product Development Milestones 51
Featured News & Press Releases 51
May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations 51
May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets 51
Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 52
Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference 53
Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries 53
Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen 53
Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen 54
Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012 55
Sep 24, 2012: Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen For Chronic Fatigue Syndrome 55
Aug 14, 2012: FDA Accepts Complete Response Submission Regarding Ampligen New Drug Application For Chronic Fatigue Syndrome 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products under Development for Fatigue, H2 2014 7
Number of Products under Development for Fatigue - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Fatigue - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 15
Fatigue - Pipeline by Hemispherx Biopharma, Inc., H2 2014 16
Fatigue - Pipeline by MultiCell Technologies, Inc., H2 2014 17
Fatigue - Pipeline by Alder Biopharmaceuticals Inc., H2 2014 18
Fatigue - Pipeline by Biovista Inc., H2 2014 19
Fatigue - Pipeline by PharmaLundensis AB, H2 2014 20
Fatigue - Pipeline by Merz Pharmaceuticals GmbH, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Assessment by Combination Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Fatigue Therapeutics - Recent Pipeline Updates, H2 2014 42
Fatigue - Dormant Projects, H2 2014 50